The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 16 April 2026•Updated 17 April 2026•

1 min read

Pool Corp and West Pharmaceutical Set for Q1 Earnings Amid Major Buyback Plans

Key Facts

1Pool Corporation is scheduled to release Q1 earnings on April 23rd with a projected EPS of $5.34.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: Added Wells Fargo's price target reduction for Pool Corp and included the broader analyst consensus average and potential upside.

Financial markets are closely watching Pool Corporation and West Pharmaceutical Services as they prepare to release their Q1 financial results on April 23rd. Recently, Wells Fargo adjusted its price target for Pool Corp (POOL) to $215 from $230, maintaining an 'Equal-Weight' rating. Despite this adjustment, the average analyst target price for POOL stands at $264.47, suggesting a potential upside of 25.71%. Meanwhile, West Pharmaceutical expects an EPS of $1.68 on revenue of approximately $779.675 million, bolstered by a $1.0 billion share buyback program. These developments highlight a more cautious valuation from some institutions even as consensus remains optimistic. Analysts will be monitoring whether both companies can meet or exceed these estimates amid current market conditions.